Dossier assessment
Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with active psoriatic arthritis
Patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: hint of minor added benefit. Patients who have had an inadequate response or who have been intolerant to a prior therapy with biologic disease-modifying antirheumatic drugs (bDMARDs): added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.
Project details
- Project no.
- A21-15
- Commission
- Commission awarded on 01.03.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15
Status: Commission completed
-
Dossier assessment
Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed